Galera Therapeutics, INC Schedule 13D activist filings
Filed when an investor crosses five percent and intends to influence the company — the activist disclosure.
OQB
Parvinder Singh Hyare reports beneficial ownership of 13,521,921 shares of Galera Therapeutics following a mandatory conversion of Series B Preferred Stock.
OQB
Emerald Bioventures, LLC and Timothy Opler have increased their beneficial ownership in Galera Therapeutics to 30.2% following a mandatory conversion of Series B Preferred Stock.
OQB
Emerald Bioventures, LLC and Timothy Opler have filed a Schedule 13D, disclosing beneficial ownership of approximately 26.5% of Galera Therapeutics, Inc. common stock, following a merger and private placement.
OQB
Nancy T. Chang, a director of Galera Therapeutics, Inc., has updated her beneficial ownership following a merger and private placement, now holding 5.9% of the company's common stock.